- $125.62m
- -$28.41m
U.S. STOCKS ON THE MOVE-Array, Biora, energy firms
U.S. STOCKS ON THE MOVE-U.S. Steel, Arcutis, Alphabet
Kinnate Biopharma slumps on stopping development of lead drug as solo cancer therapy
U.S. RESEARCH ROUNDUP-CNH Industrial, Deere & Co, Hancock Whitney
Brief: Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization And Workforce Restructuring
Brief: Kinnate Inc - In Connection With Plan, Expects To Incur One-Time Costs Of About $2.0 Million, Primarily In Q3, Relating To Severance And Related Benefits
Kinnate Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Kinnate Biopharma Q2 Basic EPS USD -0.68
Kinnate Biopharma Inc expected to post a loss of 75 cents a share - Earnings Preview
Kinnate Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Kinnate Biopharma Inc Reports First Quarter 2023 Financial Results
Brief: Kinnate Biopharma posts Q1 basic EPS USD -0.73
Kinnate Biopharma Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Orbimed Advisors LLC Reports 13.1% Stake In Kinnate Biopharma As Of April 28 - SEC Filing
U.S. RESEARCH ROUNDUP-First Solar, Lockheed Martin, MSCI
Brief: Kinnate Biopharma Inc. Adds Two New Drug Candidates To Its Growing Targeted Oncology Pipeline And Provides Cash Runway Guidance
Brief: First Report Of Positive Dose Escalation Data Supports Best-In-Class Profile For Investigational Exarafenib As A Single Agent And In Combination With Binimetinib In Braf-Altered Cancers And Nras Mutant Melanoma
Brief: Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results And Recent Corporate Updates